Evidation is a two-sided platform connecting individuals and enterprises. On the consumer side, we provide value to over 4 million individuals across the US who are highly motivated to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Evidation runs programs for enterprises to get actionable evidence in three areas: disease burden and patient impact, patient segmentation and identification, disease event and progression modelling. We deploy a proven approach, incorporating our experience with over 200 research programs, to reliably delivers results. Given our connectivity with highly engaged individuals, we deliver faster and more cost-effectively.
Evidation conducted the first study to assess the everyday impact of constipation, a commonly overlooked condition. Through our network of individuals, our team recruited over 1,500 participants with lower gut health issues and had high compliance rates with an intensive 12-week study protocol. In under one year, we delivered results which have the potential to get more patients on the right treatment faster.
Using PGHD, we could identify patients whose asthma symptoms were not adequately managed on current treatments. In one week, Evidation recruited over 14,000 individuals with asthma via our Achievement population and delivered results in under 12 weeks. For two patients below who appear identical in claims data – the same diagnosis (moderate-to-severe asthma) and treatment (LABA/ICS) – with PGHD, we can identify that one patient’s asthma is not suitably controlled on existing treatment. Similarly, we see clear splits in activity sleep behaviors that may indicate how well controlled a patient’s asthma is. These findings enable early identification of individuals with inadequate symptom control, who could benefit from treatment.
Through PGHD, Evidation detected and measured the impact of flares in an autoimmune condition. We were able to detect flares through measured changes in behavior and quantify flare impact and recovery over time. This foundation has the potential to help accelerate time to diagnosis and getting patients on the right treatment faster.